Oral Androgen Receptor Pathway Agents are Changing PCa+ Treatment

February 24, 2014

Oral AR Pathway Agents are Changing Prostate Cancer Treatment

New theories for castration-resistant prostate cancer have led to the development of new oral androgen receptor pathway agents. In this presentation, Leonard Gomella, MD focuses on two of these agents – abiraterone acetate and enzalutamide. He presents recent data from the registration trials of each agent.

Leonard G. Gomella, MD, FACS
Thomas Jefferson University Hospital